Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex vivo T-cell therapies. The deal calls for Prime Medicine to design ...
Prime Medicine has partnered with Bristol Myers Squibb to develop ex vivo T-cell therapies. BMS will pay $55 million up front and invest another $55 million, but the partnership could be worth more ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, ...
As part of a new agreement, employees of Bristol Hospital will receive a 20 percent tuition discount for undergraduate, graduate, or non -credit professional development certificate programs. The ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer announced today, an expanded collaboration with Bristol Myers Squibb (NYSE: BMY) to develop ...
Professor Davey Smith's contributions to medical research have marked him as among the most highly recognised scientists ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback